Literature DB >> 12213409

Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen.

D T O'Hagan1, M Singh, J Kazzaz, M Ugozzoli, M Briones, J Donnelly, G Ott.   

Abstract

A synthetic oligonucleotide containing a previously identified adjuvant active CpG DNA sequence was evaluated for its ability to augment antibody and CTL responses to p55 gag from HIV-1 in mice. Surprisingly, the CpG oligonucleotide, although, it had previously been described as the most potent adjuvant sequence in mice for the particulate HbsAg, was ineffective when used in a simple combination with urea-solubilized p55 antigen. However, a potent adjuvant effect was observed with the CpG sequence when it was formulated with emulsions. Enhancement of antibody titer by CpG emulsion formulations was observed with urea-solubilized p55 antigen, however, significantly higher titers were obtained with p55 bound to polylactide-co-glycolide microparticles. In both cases IgG2a was enhanced in the presence of CpG. It appears likely that presentation of CpG with emulsions and particulate antigens enhances their delivery into antigen presenting cells (APC) and results in more effective presentation of antigen and adjuvant. To support this hypothesis, preliminary in vitro studies were undertaken to show upregulation of CD86 on mouse bone marrow-derived dendritic cells (BMDC) in vitro, following incubation with CpG formulations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213409     DOI: 10.1016/s0264-410x(02)00272-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.

Authors:  Yuan Fang; Thomas Rowe; Alberto J Leon; David Banner; Ali Danesh; Luoling Xu; Longsi Ran; Steven E Bosinger; Yi Guan; Honglin Chen; Cheryl C Cameron; Mark J Cameron; David J Kelvin
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

3.  Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

Authors:  Manmohan Singh; James Chesko; Jina Kazzaz; Mildred Ugozzoli; Elaine Kan; Indresh Srivastava; Derek T O'Hagan
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

4.  Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Authors:  Tracey J Harvey; Itaru Anraku; Richard Linedale; David Harrich; Jason Mackenzie; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  Molecular and cellular signatures of human vaccine adjuvants.

Authors:  F Mosca; E Tritto; A Muzzi; E Monaci; F Bagnoli; C Iavarone; D O'Hagan; R Rappuoli; E De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

6.  Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Authors:  Brian Burke; Victor Raúl Gómez-Román; Ying Lian; Yide Sun; Elaine Kan; Jeffrey Ulmer; Indresh K Srivastava; Susan W Barnett
Journal:  Virology       Date:  2009-02-27       Impact factor: 3.616

Review 7.  Novel approaches to vaccine delivery.

Authors:  Derek T O'Hagan; Rino Rappuoli
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

8.  CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses.

Authors:  Michael J McCluskie; Risini D Weeratna; Dana M Evans; Shawn Makinen; Debbie Drane; Heather L Davis
Journal:  Biomed Res Int       Date:  2013-03-23       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.